CDK4 and breast cancer: However, when in the current study, Nehme et al (2025) treated ER+ (estrogen receptor) or TNBC (triple-negative breast cancer) breast cancer cells with the CDK4/6i abemaciclib, they observed a reversible senescent-like state resistant to a variety of commonly used senolytic drugs.